US EditionPublished • loading... • Updated
Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
- Akeso's Ivonescimab has received Breakthrough Therapy Designation from the Center for Drug Evaluation for treating triple-negative breast cancer, marking the fourth designation it has received.
- This designation signifies Ivonescimab's substantial clinical benefit across multiple major cancer types, according to Akeso.
- Ivonescimab is part of 14 Phase III clinical trials worldwide, enhancing its development and approval prospects.
- It is recognized as the world's first bispecific antibody utilizing a synergistic 'immunotherapy plus anti-angiogenesis' mechanism.
Insights by Ground AI
78 Articles
78 Articles
Rutland Herald+76 Reposted by 76 other sources
Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
HONG KONG, Nov. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC) has been granted Breakthrough Therapy Designation (BTD) by the…
Coverage Details
Total News Sources78
Leaning Left9Leaning Right4Center26Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 23%
C 67%
Factuality
To view factuality data please Upgrade to Premium
